Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Pavel Alexandrov

Anesthesiology Bronx, NY Medical Doctor

NPI 1841358330 CMS profile 219944

1400 Pelham Pkwy S, Bronx, NY 10461

Open in the dashboard

General payments

$723

30 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Pavel Alexandrov of Bronx, NY is reported in the CMS Open Payments database as having received $723 across 30 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $107 5
2021 General $32 2
2020 General $38 2
2019 General $546 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pavel Alexandrov
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Pavel Alexandrov were reported at $0. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Pavel Alexandrov Anesthesiology median Middle half National median
2019 $546 $72 $23–$151 $163
2020 $38 $36 $17–$120 $114
2021 $32 $49 $21–$135 $132
2022 $107 $52 $22–$144 $149
2023 $0 $53 $23–$143 $160
2024 $0 $55 $25–$150 $164
2025 $0 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Smith+Nephew, Inc. $391 11 payments
  2. Horizon Therapeutics plc $183 9 payments
  3. Daiichi Sankyo Inc. $136 9 payments
  4. AstraZeneca Pharmaceuticals LP $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $723 30 payments
Products named General payments · program years 2019–2022
  1. Regeneten $306 8 payments
  2. PENNSAID $183 9 payments
  3. Morphabond ER $136 9 payments
  4. Mosaicplasty $85 3 payments
  5. MOVANTIK $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,898

Median for Interventional Pain Management: 1,220

Drug cost

$92,647

Median for Interventional Pain Management: $39,344

Branded share of claims

31.6%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 27 $19,852
Movantik Naloxegol Oxalate Brand 24 $12,503
Linzess Linaclotide Brand 12 $12,268
Diclofenac Sodium Generic 183 $11,540
Lidocaine Generic 46 $7,350
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 309 $6,827
Naloxone Hcl Generic 100 $6,527
Oxycodone Hcl Generic 190 $2,775
Endocet Oxycodone Hcl/Acetaminophen Brand 74 $2,303
Gabapentin Generic 194 $1,869

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$29,786

Of which drugs: $5,038

Medicare patients

75

Average age 69

Services billed

1,347

43 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Ischemic heart disease 29%
Depression 29%
Heart failure 23%
Chronic kidney disease 21%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 172 $128

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

30 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record